Adipocytokines in rheumatoid arthritis and obesity;Adipozytokine bei rheumatoider arthritis und adipositas

Wiener Medizinische Wochenschrift

Volumn 160, Issue 15-16, 2010, Pages 391-398

  Fagerer, Nicola ^a   Kullich, Werner ^a  

^a LUDWIG BOLTZMANN INSTITUTE FOR LUNG VASCULAR RESEARCH   (Austria)

Author keywords

Adiponectin; Cardiovascular diseases; Leptin; Obesity; Rheumatoid arthritis; Visfatin

Indexed keywords

ADIPOCYTOKINE; ADIPONECTIN; C REACTIVE PROTEIN; CD40 LIGAND; LEPTIN; NICOTINAMIDE PHOSPHORIBOSYLTRANSFERASE;

ARTICLE; BODY MASS; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CONTROLLED STUDY; CORRELATION ANALYSIS; ERYTHROCYTE SEDIMENTATION RATE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; OBESITY; PARAMETER; PROTEIN EXPRESSION; RHEUMATOID ARTHRITIS; T LYMPHOCYTE;

ADIPOKINES; ADIPONECTIN; ADULT; AGED; AGED, 80 AND OVER; ARTHRITIS, RHEUMATOID; BLOOD SEDIMENTATION; BODY MASS INDEX; C-REACTIVE PROTEIN; CARDIOVASCULAR DISEASES; CD40 LIGAND; CYTOKINES; FEMALE; HUMANS; INFLAMMATION MEDIATORS; LEPTIN; MALE; MIDDLE AGED; NICOTINAMIDE PHOSPHORIBOSYLTRANSFERASE; OBESITY; REFERENCE VALUES; RISK FACTORS; STATISTICS AS TOPIC; YOUNG ADULT;

EID: 78149336027     PISSN: 00435341     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10354-010-0808-z     Document Type: Article

References (38)

1. Neumann E, Knedla A, Meier F, et al. Adipozytokine als treibende Faktoren bei rheumatoider Arthritis. Z Rheumatol, 66:139-141, 2007.
2. Ouchi N, Kihara S, Arita Y, et al. Novel modulator for endothelial adhesion molecules: adipocyte-derived plasma protein adiponectin. Circulation, 100:2473-2476, 1999.
3. Yokota T, Oritani K, Takahashi I, et al. Adiponectin, a new member of the family of soluble defense collagens, negatively regulates the growth of myelomonocytic progenitors and the functions of macrophages. Blood, 96:1723-1732, 2000.
4. Moschen AR, Kaser A, Enrich B, et al. Visfatin, an adipocytokine with proinflammatory and immunmodulating properties. J Immunol, 178:1748-1758, 2007.
5. Otero M, Lago R, Gomez R, et al. Changes in plasma levels of fatderived hormones adiponectin, leptin, resistin and visfatin in patients with rheumatoid arthritis. Ann Rheum Dis, 65:1198-1201, 2006.
6. Niksic F, Burmucic K, Kullich W, et al. Kardiovaskuläre Manifestationen bei entzündlich rheumatischen Erkrankungen. Wien Med Wochenschr, 152:220-222, 2002.
7. World Medical Association General Assembly, Tokio. World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects. Int Bioethique, 15:124-129, 2004.
8. WHO Consultation on Obesity. Obesity. Preventing and managing the global epidemic. Genf: Weltgesundheitsorganisation; 1998.
9. Fonseca-Alaniz MH, Takada J, Alonso-Vale MI, et al. Adipose tissue as an endocrine organ: from theory to practice. J Pediatr (Rio J), 83:192-103, 2007.
10. Friedman JM. The function of leptin in nutrition, weight, and physiology. Nutr Rev, 6 (10 Pt 2): S1-S14, 2002; discussion S68-S84, 85-87.
11. Considine RV, Sinha MK, Heiman ML, et al. Serum immunoreactiveleptin concentrations in normal-weight and obese humans. N Engl J Med, 334:292-295, 1996.
12. Matarese G, Moschos S, Mantzoros CS. Leptin in immunology. Z J Immunol, 173:3137-3142, 2005.
13. Park MC, Lee SW, Choi ST, et al. Serum leptin levels correlate with interleukin-6 levels and disease activity in patients with ankylosing spondylitis. Scand J Rheumatol, 36:101-106, 2007.
14. Bokarewa M, Bokarewa D, Hultgren O, et al. Leptin consumption in the inflamed joints of patients with rheumatoid arthritis. Ann Rheum Dis, 62:952-956, 2003.
15. Gunaydin R, Kaya T, Atay A, et al. Serum leptin levels in rheumatoid arthritis and relationship with disease activity. South Med J, 99:1078-1083, 2006.
16. Wislowska M, Rok M, Jaszczyk B, et al. Serum leptin in rheumatoid arthritis. Rheumatol Int, 27:947-954, 2007.
17. Yamagishi SI, Edelstein D, Du XL, et al. Leptin induces mitochondrial superoxide production and monocyte chemoattractant protein-1 expression in aortic endothelial cells by increasing fatty acid oxidation via protein kinase A. J Biol Chem, 276:25096-25100, 2001.
18. Cooke JP, Oka RK. Does leptin cause vascular disease? Circulation, 106:1904-1905, 2002.
19. Konstantinides S, Schafer K, Koschnick S, et al. Leptindependent platelet aggregation and arterial thrombosis suggests a mechanism for atherothrombotic disease in obesity. J Clin Invest, 108:1533-1540, 2001.
20. Radovits BJ, Popa-Diaconu DA, Popa C, et al. Disease activity as a risk factor for myocardial infarction in rheumatoid arthritis. Ann Rheum Dis, 68:1271-1276, 2009.
21. Stavropoulos-Kalinoglou A, Metsios GS, Panoulas V, et al. Associations of obesity with modifiable risk factors for the development of cardiovascular disease in patients with rheumatoid arthritis. Ann Rheum Dis, 68:242-245, 2009.
22. Laurberg TB, Frystyk J, Ellingsen T, et al. Plasma Adiponectin in patients with active, early, and chronic rheumatoid arthritis who are steroid-and disease-modifying antirheumatic drug-naïve compared with patients with osteoarthritis and controls. J Rheumatol, 36:1885-1891, 2009.
23. Saltevo J, Kautiainen H, Vanhala M. Gender differences in adiponectin and low-grade inflammation among individuals with normal glucose tolerance, prediabetes, and type 2 diabetes. Gend Med, 6:463-470, 2009.
24. He H, Ni Y, Chen J, et al. Sex difference in cardiometabolic risk profile and adiponectin expression in subjects with visceral fat obesity. Transl Res, 155:71-77, 2010.
25. Lau CW, Dhillon B, Yan H, et al. Adipokines: molecular links between obesity and atherosclerosis. Am J Physiol Heart Circ Physiol, 288: H2031-H2041, 2005.
26. Guzik TJ, Mangalat D, Korbut R. Adipocytokines - Novel link between inflammation and vascular function? J Physiol Pharmacol, 57:505-528, 2006.
27. Otero M, Lago R, Gomez R, et al. Towards a pro-inflammatory and immunmodulatory emerging role of leptin. Rheumatology (Oxf), 45:944-950, 2006.
28. Zahorska-Markiewicz B, Olszanecka-Glinianowicz M, Janowska J, et al. Serum concentration of visfatin in obese women. Metabolism, 56:1131-1134, 2007.
29. Körner A, Garten A, Blüher M, et al. Molecular characteristics of serum visfatin and differential detection by immunoassays. J Clin Endocrinol Metab, 92:4783-4791, 2007.
30. Ouchi N, Kihara S, Funahashi T, et al. Reciprocal association of C-reactive protein with adiponectin in blood stream and adipose tissue. Circulation, 107:671-674, 2003.
31. Lemieux I, Pascot A, Prud́homme D, et al. Elevated C-reactive protein: another component of the atherothrombotic profile of abdominal obesity. Arterioscler Thromb Vasc Biol, 21:961-967, 2001.
32. Oki K, Yamane K, Kamei N, et al. Circulating visfatin level is correlated with inflammation, but not with insulin resistance. Clin Endocrinol (Oxf), 67:796-800, 2007.
33. Berner B, Wolf G, Hummel KM, et al. Increased expression of CD40 ligand (CD154) on CD4+ T cells as a marker of disease activity in rheumatoid arthritis. Ann Rheum Dis, 59:190-195, 2000.
34. Toubi E, Shoenfeld Y. The role of CD40-CD154 interactions in autoimmunity and the benefit of disrupting this pathway. Autoimmunity, 37:457-464, 2004.
35. Tamura N, Kobayashi S, Kato K, et al. Soluble CD154 in rheumatoid arthritis: elevated plasma levels in cases with vasculitis. J Rheumatol, 28:2583-2590, 2001.
36. Corson MA. Emerging inflammatory markers for assessing coronary heart disease risk. Curr Cardiol Rep, 11:452-459, 2009.
37. Contin C, Pitard V, Itai T, et al. Membrane-anchored CD40 is processed by the tumor necrosis factor-alpha-converting enzyme. Implications for CD40 signaling. J Biol Chem, 278:32801-32809, 2003.
38. Sanchez C, Mateus MM, Defresne M-P, et al. Metabolism of human articular chondrocytes cultured inalginate beads. Longterm effects of interleukin 1 β and nonsteroidal anti-inflammatory drugs. J Rheumatol, 29:772-782, 2002.